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Biotin deficiency causes an inflammatory bowel disease–like
state, but biotin supplementation has never been tested as a
therapeutic in established models for inflammatory bowel
disease. We found that biotin therapy leads to delayed onset
and severity of dextran sodium sulfate colitis mediated by
decreased activation of nuclear factor-kB.
BACKGROUND & AIMS: Biotin is a water-soluble vitamin that
is indispensable for human health. Biotin deficiency can
cause failure-to-thrive, immunodeficiency, alopecia, derma-
titis, and conjunctivitis. We previously reported that biotin
deficiency also can lead to severe colitis in mice, which is
completely reversed with supplementation. Our aim in this
study was to determine if high-dose biotin supplementation
can provide a therapeutic benefit in a preclinical model for
inflammatory bowel disease (IBD) and to identify the mo-
lecular mechanism by which this occurs.
METHODS: Mice were challenged with dextran sodium sul-
fate to induce colitis and were treated with 1 mmol/L biotin
to induce or maintain remission. Clinical response was
monitored by the Disease Activity Index and fecal calpro-
tectin levels. The colon tissue was investigated for histology,length, as well as expression of inflammatory cytokines
(interleukin 6, tumor necrosis factor-a, interleukin 1b), in-
testinal permeability, tight junctions (zonula occludens-1 and
claudin-2), and the transcription factor nuclear factor-kB
(NF-kB).
RESULTS: Biotin therapy led to delayed onset and severity of
colitis as well as accelerated healing. There was improvement
in the Disease Activity Index, fecal calprotectin levels, colon
length, and histology. In addition, biotin-treated mice had
reduced expression of inflammatory cytokines, reduced intes-
tinal permeability, and reduced activation of NF-kB.
CONCLUSIONS: Oral supplementation with biotin provides
benefit for maintenance and induction of remission in the
dextran sodium sulfate preclinical model for IBD. Biotin does
this by reducing the activation of NF-kB, which prevents the
production of inflammatory cytokines and helps maintain the
integrity of the intestinal barrier. Clinically, the NF-kB pathway
is important in the development of IBD and this finding sug-
gests that biotin may have therapeutic potential for patients
with IBD. (Cell Mol Gastroenterol Hepatol 2020;9:557–567;
https://doi.org/10.1016/j.jcmgh.2019.11.011)
Keywords: Biotin; Inflammatory Bowel Disease; Colitis;
Therapeutics.
558 Skupsky et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 4iotin is a water-soluble vitamin and an essentialAbbreviations used in this paper: DAI, Disease Activity Index; DSS,
dextran sodium sulfate; ELISA, enzyme-linked immunosorbent assay;
FITC, fluorescein isothiocyanate; GI, gastrointestinal; IBD, inflamma-
tory bowel disease; IL, interleukin; NF-kB, nuclear factor-kB; PCR,
polymerase chain reaction; SMVT, sodium-dependent multivitamin
transporter; TNF, tumor necrosis factor; UC, ulcerative colitis.
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https://doi.org/10.1016/j.jcmgh.2019.11.011Bmicronutrient that must be obtained from exogenous
sources such as dairy, liver, egg yolk, and vegetables, or
from commensal bacteria.1 Its classic role is as a covalently
bound coenzyme for cytoplasmic carboxylases used in fatty
acid homeostasis, gluconeogenesis, and other metabolic
pathways,2 but emerging data also have identified a role in
cellular stress response,3 gene regulation,4,5 and immune
responses.6–10 Clinically, biotin deficiency, whether induced
by dietary means or by mutation of the intestinal biotin
uptake system (ie, sodium-dependent multivitamin trans-
porter [SMVT], Slc5a6), is associated with failure to thrive,
microcephaly, osteoporosis, immunodeficiency, alopecia,
dermatitis, and conjunctivitis.11,12 In our previous studies to
determine the relative contribution of SMVT toward total
carrier-mediated biotin absorption, we made the serendip-
itous finding that SMVT knockout mice also develop colonic
crypt abscesses, neutrophil infiltration, submucosal edema,
and dysplastic changes.13 In the current report, we extend
our findings on the effect of biotin deficiency and show that
dietary-induced biotin deficiency leads to an increase in the
inflammatory marker fecal calprotectin, which is used
routinely to monitor the progression of patients with in-
flammatory bowel disease (IBD).14 Importantly, we show
that these mice fully recover from their IBD-like state with
biotin supplementation.
Our goal in this study was to determine if biotin sup-
plementation also could be used as treatment in a pre-
clinical model for IBD. For this, we examined the most
widely used experimental model for IBD, the dextran so-
dium sulfate (DSS) colitis model.15,16 Mice were challenged
with DSS in drinking water to induce colitis; after 7 days
they had increased weight loss, Disease Activity Index
(DAI) scores, calprotectin, proinflammatory cytokines, in-
testinal permeability, and histologic scores, as expected. In
addition, they also had decreased levels of the biotin
transporter SMVT. The clinical relevance of this finding was
confirmed when we identified that there also was a
decrease of SMVT in biopsy specimens from patients with
active ulcerative colitis (UC). Next, we used the DSS model
to examine the ability of biotin supplementation to
ameliorate signs of colitis and found that all parameters
measuring the development of colitis trended toward
baseline with biotin therapy. Finally, we identified the
mechanism by which biotin exerts its therapeutic effect by
showing decreased levels of active phosphorylated nuclear
factor-kB (NF-kB) in biotin-treated mice. NF-kB is a pleio-
tropic transcription factor that drives expression of pro-
survival genes in intestinal epithelial cells, and it also
coordinates expression of proinflammatory genes from
cells of the innate and adaptive immune system.17,18
Increased inflammation promotes epithelial permeability,
which exacerbates colitis. Indeed, NF-kB is a pivotal regu-
lator in the development of IBD.19,20
In recent years, several new medications have been
approved, and many more are under development, for the
treatment of UC and Crohn’s disease.21–25 For each medi-
cation, there is a risk-to-benefit evaluation to consider and,depending on the side-effect profile, patients will need to be
monitored for adverse events.26 We propose that biotin
would be an ideal medication for IBD therapy because it can
be delivered orally and has minimal risk for complications.
Notably, biotin deficiency often is overlooked in the setting
of IBD and there have been several reports of biotin defi-
ciency in patients with IBD.27–31 The data from mice treated
with biotin to prevent or treat colitis suggest that biotin
therapy may provide benefit to patients with IBD.
Results
The Dietary Model for Biotin Deficiency Induces
an IBD-Like State, Which Is Prevented With
Biotin Supplementation
In the first series of experiments, we examined dietary
biotin deficiency to further characterize the phenotype that
develops. Mice received a biotin-deficient diet and showed
the first signs of disease after 7 weeks when they began to
develop alopecia and weight loss. As time progressed, they
had decreased activity levels, hunched posture, poor skin
turgor, and their stools became soft and bloody. This was
prevented with 1 mmol/L biotin supplementation added to
their drinking water (Figure 1A and B). We further tested
stool samples at week 14 for fecal calprotectin, a noninva-
sive biomarker for inflammation in the gastrointestinal (GI)
tract, and found that it was increased in mice with biotin
deficiency (Figure 1C). Inflammation was most pronounced
in the cecum of mice with biotin deficiency and histology
showed loss of goblet cells, altered crypt architecture,
infiltration of lymphocytes and neutrophils, with expansion
of the lamina propria. Mice treated with biotin supplemen-
tation had normal histology without colitis (Figure 1D).
Although no mouse model entirely recapitulates patients
with IBD, this model reproduces many of the findings
including weight loss, bloody diarrhea, increased fecal cal-
protectin, altered crypt architecture, and infiltration of
neutrophils and lymphocytes to the mucosa and submucosa.
The Biotin Transport Pathway Is a Clinically
Relevant Target for IBD Treatment
Because biotin therapy was able to reverse the IBD-like
features described earlier, the next series of experiments
were designed to validate if the biotin transport pathway
would be a relevant drug target in IBD. To address a role for
biotin in the treatment of colitis, we induced severe disease
in mice using 3% DSS in drinking water. The mice in this
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Figure 1. Chronic biotin deficiency induces an IBD-like state that completely resolves with biotin supplementation.
C57BL/6J mice received a control diet or a biotin-deficient diet with and without 1 mmol/L biotin supplementation for 14
weeks. (A) Representative images comparing a control mouse, a mouse on the deficient diet ,and a mouse that received the
deficient diet and treatment with 1 mmol/L biotin. (B) Body weight was recorded weekly for mice in each group, significance
was calculated relative to the BD diet group. (C) A stool pellet was collected from mice in each group the day before death and
used to quantify the fecal calprotectin level. (D) Representative histology from the cecum of a mouse in each group. Mice with
biotin deficiency have erosions (arrowheads), loss of goblet cells, and altered crypt architecture with increased infiltration of
lymphocytes and neutrophils into the lamina propria (arrows), and expansion of the submucosa, while mice that were sup-
plemented with biotin did not have cecal inflammation. *P < .05, **P < .01, and ***P < .001. BD, biotin deficiency.
2020 Biotin Supplementation Ameliorates Colitis 559model typically develop a robust response within 7 days
that can be measured by standard parameters including
DAI, colon length, and histologic scoring (Figure 2A–E). We
wanted to study the biotin transport pathway in this acute
model for colitis and found that the localized biotin trans-
port pathway in the colon was down-regulated, as judged
from protein isolated from the distal colon to quantify
expression of SMVT (Figure 2F). These results suggested
that physiologic biotin uptake may be limited in the setting
of colitis.
To determine if there is clinical relevance of these find-
ings, we quantified SMVT expression by real-time poly-
merase chain reaction (PCR) using tissue from patients with
colitis and controls. We found that SMVT was decreased
significantly in patients with moderate/severe UC compared
with controls (Figure 2G). To extend this finding, we
reviewed a larger, publicly available gene expression data-
base32 (data accessible at NCBI GEO database, accession
GDS3268) with 202 biopsy specimens taken from patients
with controlled UC, active UC, and healthy controls.33 We
searched for expression levels of the SMVT gene, Slc5a6, in
the sigmoid colon and the data have been normalized to
samples from patients without disease. Interestingly, SMVT
is reduced significantly in patients with inflamed UC, but
there is no difference between healthy controls and patients
with uninflamed UC (Figure 2H). Overall, these findings
show that in mice with DSS colitis and in human beings with
active UC, the biotin transport pathway is altered in thecolon and this raises the possibility that it could be a target
for therapy.Biotin Therapy Helps Maintain Remission in DSS
Colitis
To determine if biotin can be used as a therapeutic for
the maintenance of remission to colitis, we used a 1.5% DSS
model to induce mild/moderate colitis. Starting with healthy
mice, 1 group received 1 mmol/L biotin in their drinking
water for 1 week before DSS challenge. On day 0, the
experimental and treatment groups had DSS added to
drinking water and the treatment group also was continued
on biotin (Figure 3A). An additional control group did not
receive biotin or DSS. We found that disease in the biotin
treatment group was attenuated in comparison with the
mice without supplementation. In addition, the onset of
disease was delayed, and the peak of disease was decreased
with biotin therapy, as measured by DAI (Figure 3B). The
colons from DSS challenged mice contained blood and were
shortened significantly compared with controls and those
that received DSS with biotin therapy. There was no dif-
ference between mice that received biotin therapy and
controls lacking DSS exposure (Figure 3C and D). Fecal
calprotectin also was quantified by enzyme-linked immu-
nosorbent assay (ELISA) and found to be increased in the
DSS group compared with controls and mice that received
DSS with biotin therapy. Again, there was no significant
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mice treated with DSS and
controls. DSS-treated
mice developed mucosal
erosion (arrowheads), with
loss of goblet cells, altered
crypt architecture, and
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and lymphocytes (arrows).
(E) Total histologic score.
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and normalized to b-actin
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560 Skupsky et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 4difference between the group that received biotin therapy
and the no-DSS control (Figure 3E). Finally, histology
showed mucosal erosion, distorted crypts, loss of goblet
cells, and infiltration of neutrophils and lymphocytes in the
mucosal and submucosal layers of the colon wall of mice
that received DSS. In contrast, mice that received biotin
treatment maintained much of the mucosal lining with well-
preserved crypts and goblet cells, and they had only mild
infiltration into the lamina propria (Figure 3F). Histologic
scoring confirmed significant improvement in colitis with
biotin therapy (Figure 3G). Overall, these data show that
biotin therapy helps to attenuate the development of colitis.Biotin Therapy Enhances Induction of Remission
to DSS Colitis
The next set of experiments were designed to determine if
there is a role for biotin therapy in the induction of remission
to colitis. Mice received 1.5% DSS in their drinking water for 7
days to induce moderate colitis. On day 0, the DSS was
removed and half the mice receivedwater, while the other half
received therapy with 1 mmol/L biotin. Again, there was a
control group that did not receive biotin or DSS. The groups
were monitored until day 4 when the experiment was ended
and all mice were killed (Figure 4A). Mice that received biotin
therapy recovered more quickly with complete resolution of
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Figure 3. Biotin therapy
helps maintain remission
and ameliorate the
development of colitis.
(A) Experimental protocol.
(B) DAI was calculated
daily and significance is
shown for biotin treatment.
(C) On day 7, the mice
were killed and a repre-
sentative image of a colon
from each group is shown.
(D) Average colon length
for each group. (E) A stool
pellet was collected from
mice in each group before
killing and used to quantify
the fecal calprotectin level.
(F) Representative histol-
ogy from the distal colon
of a mouse in each group.
DSS-treated mice had
mucosal erosion (arrow-
heads) and substantial
infiltration of neutrophils
and lymphocytes in the
lamina propria with loss of
crypts and goblet cells
(arrows). (G) Total histo-
logic score. *P < .05, **P <
.01, and ***P < .001. max,
maximum.
2020 Biotin Supplementation Ameliorates Colitis 561disease, asmeasured by DAI (Figure 4B). The colons frommice
that had received only water after DSS appeared shortened
and atrophic compared with mice that had received biotin
therapy and the no-DSS control. Nearly all the mice in all
groups had solid stools by that point, although the average
colon length still was shortened in the group that had received
only water after DSS. There was no difference between mice
that received biotin induction therapy and controls (Figure 4C
and D). The fecal calprotectin level was increased in the group
that received only water after DSS, compared with mice that
received biotin therapy and controls. Again, there was no
significant difference between the group that received biotin
therapy and the control group (Figure 4E). Histology in mice
fromboth groups showedmarked improvement from the peak
of disease, but the group that received onlywater still hadmild
crypt loss and neutrophil and lymphocyte infiltration
(Figure 4F and G). Overall, these data indicate that biotin
therapy is able to accelerate healing during induction of
remission.
Biotin Therapy Leads to a Reduction in
Inflammatory Cytokines and Intestinal
Permeability
We next examined localized cytokine production to
investigate the mechanism by which biotin was able toameliorate colitis in the models for both maintenance and
induction of remission. We previously have seen that in-
flammatory cytokines are up-regulated in the setting of
biotin deficiency34 and that those cytokines can be
normalized with biotin supplementation.35 To determine if
there were similarities between the biotin deficiency and
the DSS colitis models, we examined 3 proinflammatory
cytokines that have a pivotal role in the pathogenesis of IBD:
interleukin (IL)6, tumor necrosis factor (TNF)a, and
IL1b.36–38 Samples from the distal colons of mice in the
maintenance of remission experiment were assayed by
quantitative real-time-PCR. IL6 levels were increased
significantly in mice that received DSS, although they were
near baseline with biotin supplementation. TNFa and IL1b
levels also were increased with DSS colitis, but cytokine
levels did not completely return to baseline levels with
biotin therapy (Figure 5A). There are similar trends for mice
during the induction of remission (Figure 5B). These data
complement earlier studies showing that biotin levels can
affect innate and adaptive immune responses.6,8–10,13,35,39
To address whether or not biotin therapy alters mucosal
permeability we performed a fluorescein isothiocyanate
(FITC)-dextran permeability assay after the induction of
remission protocol. We noted increased levels of FITC-
dextran in the plasma of mice that had received only water
Day
0 1 2 3 4
0.0
0.5
1.0
1.5
2.0
2.5
No DSS
Water
1mM Biotin* **
**
*
D
is
ea
se
 A
cƟ
vi
ty
 
In
de
x 
(D
A
I, 
m
ax
. 4
)
C
A
ED
F G
No 
DSS
No DSS Water                    1mM bioƟn
→
→
→
Water 1mM Biotin
0
2
4
6
8
*
No  DSS Water 1mM Biotin
*
N/S
Co
lo
n 
Le
ng
th
 (c
m
)
B
Fe
ca
l C
al
pr
ot
ec
Ɵ
n 
(n
g/
g 
st
oo
l)
Figure 4. Biotin therapy
accelerates induction of
remission to DSS colitis.
(A) Experimental protocol.
(B) DAI was calculated
daily and significance is
shown for biotin treatment.
(C) On day 4, the mice
were killed and a repre-
sentative image of a colon
from each group is shown.
(D) Average colon length.
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collected from mice in
each group before killing
and used to quantify the
fecal calprotectin level. (F)
Representative histology
from the distal colon of a
mouse in each group.
Mice that received only
water continued to have
moderate infiltration along
with loss of crypts and
goblet cells (arrows). (G)
Total histologic score. *P
< .05 and **P < .01. max,
maximum.
562 Skupsky et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 4after DSS exposure, whereas mice that had received biotin
therapy showed similar values to the controls that received
no DSS (Figure 6A). These data show that biotin therapy
helped reduce intestinal permeability and the results were
confirmed by examining the expression of tight junction
proteins. In the intestine, up-regulation of zonula occludens-1
is important to maintain the mucosal integrity,40 while up-
regulation of claudin-2 is associated with susceptibility to
colitis and increased intestinal permeability.41,42 Zonula
occludens-1 levels in the distal colon were decreased in mice
that had received only water after DSS, while they were close
to baseline with biotin therapy (Figure 6B). Conversely,
claudin-2 expression was increased in the distal colons of
mice that had received only water after DSS while they were
again close to baseline with biotin therapy (Figure 6C).
Overall, these data support a model in which biotin supple-
mentation helps to maintain mucosal integrity.
Biotin Therapy Reduces NF-kB Activation
Finally, we wanted to explore these changes at the mo-
lecular level to determine if NF-kB is affected by biotin
therapy. NF-kB is considered one of the primary regulators
in the development of IBD.20 The 5 proteins in the NF-kB
family dimerize and localize to the cytoplasm inunstimulated cells. Activation signals allow for nuclear
translocation of the dimers and subsequent transactivation
of target genes.20,43 The p65 protein is the most abundant
and best studied in the NF-kB family, and phosphorylation is
the starting point in its activation.43,44 We found that total
NF-kB p65 levels were unchanged with biotin therapy
(Figure 7A), while the phosphorylated active form (NF-kB
p65 [phospho S529]) was increased in mice that did not
receive biotin supplementation (Figure 7B). These results
show that biotin therapy attenuates activation of NF-kB p65
and the inflammatory cascade that follows.
Discussion
In this report, we showed that the colitis that develops
from biotin deficiency has many similarities to mouse models
for IBD including weight loss, bloody stool, increased fecal
calprotectin, and infiltration of lymphocytes and neutrophils
to the intestinal wall. Importantly, disease and this IBD-like
state can be prevented with biotin supplementation. Biotin
is one of the water-soluble vitamins with transporters in both
the small and large intestines.45 The current understanding is
that dietary biotin is absorbed primarily in the small intestine
and biotin produced by commensal bacteria is absorbed in
the large intestine. Because the colon has constant exposure
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2020 Biotin Supplementation Ameliorates Colitis 563to biotin, it absorbs a substantial amount of total biotin.46
These observations led us to evaluate if the biotin transport
pathway is affected in an established mouse model for IBD.
We used DSS to induce severe colitis, and examined mice at
the peak of disease. We found that SMVT levels in the distal
colon, where inflammation is most pronounced in the DSS
model, were reduced significantly in mice with colitis when
compared with healthy controls. The clinical relevance of this
finding was supported by comparing gene expression in pa-
tients with UC and healthy controls. We found decreased
expression of the SMVT biotin transporter in the distal colon
of patients with active UC when compared with the distal
colon of healthy controls. The same finding of decreased
SMVT expression during active disease can be found in the
proximal and descending colon as well.32 Although this as-
sociation cannot determine if reduced SMVT is a cause orBA
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Figure 6. Biotin therapy helps maintain the integrity of the
protocol received FITC-dextran by oral gavage 4 hours before
marker of intestinal permeability. (B) Quantitative real-time-PCR
junction protein zonula occludens-1 (ZO-1) and (C) claudin-2.
dehydrogenase and healthy controls. *P < .05 and **P < .01. mresult of a colitis flare, it does suggest that biotin supple-
mentation should be explored for IBD treatment.
We then tested biotin supplementation in the DSS pre-
clinical model for IBD to determine if it has a therapeutic ef-
fect. There is no expected direct interaction between biotin
and DSS.2 In the maintenance of remission model, mice began
without disease and received biotin supplementation. They
then were challenged with DSS to induce moderate colitis and
wemonitored the changes between the treatment and control
groups for 7 days. The mice receiving biotin therapy still
developed some signs of disease, but they were substantially
less severe in comparison with mice that did not receive
biotin. In biotin-treatedmice, DAI showed a delayed onset and
a reduced peak of disease, fecal calprotectin level was
reduced, and histology showed only mild lymphocyte infil-
tration compared with more pronounced erosions and cryptC
intestinal mucosa. (A) Mice from the induction of remission
killing. Plasma levels of FITC-dextran were measured as a
was performed on tissue from the distal colon to quantify tight
Data have been normalized to glyceraldehyde-3-phosphate
RNA, messenger RNA.
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564 Skupsky et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 4loss in the untreated mice. Proinflammatory cytokines IL6,
TNFa, and IL1b also were decreased in the treatment group.
We repeated a similar set of experiments using an induction of
remission model. In this model, mice began biotin therapy at
the peak of disease and we compared remission rates with
untreated mice after the DSS was removed. After 4 days on
biotin, the DAI score of treated mice had returned to baseline
and was improved significantly in comparison with untreated
mice. Similar results were seen for colon length, calprotectin,
and histology. Again, proinflammatory cytokines were
decreased. In addition, in this model, we evaluated gut
permeability and found that it was decreased with biotin
treatment and that there were increased levels of zonula
occludens-1 and decreased levels of the leaky tight-junction
protein claudin-2. These data support our previous finding
that the biotin transport pathway plays an important role in
the maintenance of mucosal integrity.34
The mechanisms underlying the pathogenesis of biotin
deficiency and biotin’s therapeutic potential remains an active
area of research and several advances have been made
recently.6,8,13,34,35,39,47–49We previously reported on an SMVT
knockoutmouse that provided evidence that the SMVT system
is exclusively responsible for intestinal biotin uptake and
deletion of SMVT is sufficient to induce colitis.2 SMVT levels
also can decrease physiologically in response to cytokine
activation of the NF-kB pathway.39 Interestingly, NF-kB has adual role in the GI tract by driving proinflammatory responses
in immune cells and by up-regulating prosurvival genes in
epithelial cells.17 However, in the setting of IBD the primary
role is orchestrating mucosal inflammation.20 In the current
study, we showed that biotin therapy is sufficient to attenuate
activation of NF-kB p65 and propose this as the underlying
mechanism of its therapeutic effect. If infiltrating cells have
reduced activation of NF-kB, then theywill produce decreased
amounts of inflammatory cytokines that subsequently will
lead to reduced intestinal permeability and maintenance of
mucosal integrity. The specific mechanism(s) linking biotin
and NF-kB is unclear but could be mediated via the different
cellular pathways that are affected by biotin availability.
Further studies are required to define this relationship.
IBD develops from a combination of genetic predisposi-
tion, environmental triggers, dysbiosis in the microbiome,
and complex interactions in the host immune system,
making it challenging to model IBD accurately in preclinical
models.50,51 As mentioned, biotin deficiency has been
identified in patients with IBD and it may have profound
implications in the GI tract that have not been fully explored.
We are optimistic that the data presented here will serve as
the foundation for future clinical studies to determine if
biotin supplementation should be used as adjunct therapy in
IBD. Biotin is available over the counter, is affordable, and it
has minimal side effects, making it an ideal therapeutic if
clinical trials can show similar efficacy to what we have seen
in this preclinical model.
Materials and Methods
All authors had access to the study data and reviewed
and approved the final manuscript.
Mice
C57BL/6J mice were purchased from Jackson Labora-
tories (Ellsworth, ME) and housed at University of California
Irvine in compliance will all University Laboratory Animal
Resources guidelines. Mice aged 8–10 weeks were used at
the start of all experiments and representative experiments
were confirmed with male and female mice to ensure there
were no sex differences. Experiments were performed in
compliance with all federal and local guidelines and
approved by the Institutional Animal Care and Use Com-
mittee and the University of California Irvine.
Biotin-Deficient and Control Diet
The biotin-deficient diet (Envigo, Madison, WI) has no
added biotin and the protein source is 300 g/kg spray-dried,
egg-white solids. Egg white is high in avidin, which bind the
luminal biotin produced by the host microbiome.7,52 The
biotin-control diet (Envigo) has the same make-up and
protein source as the deficiency diet, but is supplemented
with 0.004 g/kg biotin. Mice received the diet ad libitum and
pair-feeding was performed.
Fecal Calprotectin ELISA
Fecal calprotectin was quantified by ELISA using the
DuoSet Mouse S100A8/S100A9 Heterodimer kit (R&D
Table 1.List of Primer Sequences Used for Quantitative Real-Time-PCR
Gene name Forward and reverse primer sequences, 50-30
Mouse claudin-2 TTAGCCCTGACCGAGAAAGA; AAAGGACCTCTCTGGTGCTG
Mouse ZO-1 TTCAAAGTCTGCAGAGACAATAGC; TCACATTGCTTAGTCCAGTTCC
Mouse IL6 GAGGATACCACTCCCAACAGACC; AAGTGCATCATCGTTGTTCATACA
Mouse TNF-a CATCTTCTCAAAATTCGAGTGACAA; TCGGAGTAGACAAGGTACAACCC
Mouse IL1b CTCTCCAGCCAAGCTTCCTTGTGC; GCTCTCATCAGGACAGCCCAGGT
Mouse GAPDH CTACAGCAACAGGGTGGTGG; TATGGGGGTCTGGGATGG
Mouse SMVT CGTAGGAACTTTGGTAGCCCTGG; CTTAGGTGTGATGGGTCTCTCC
Human SMVT TGTCTACCTTCTCCATCATGGA; TAGAGCCCAATGGCAAGAGA
Human b-actin CATCCTGCGTCTGGACCT; TAATGTCACGCACGATTTCC
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ZO-1, zonula occludens-1.
2020 Biotin Supplementation Ameliorates Colitis 565Systems, Minneapolis, MN) according to the manufacturer’s
recommendations. Briefly, a stool pellet was collected,
weighed, and immediately frozen. The night before the assay,
pellets were incubated at 4C with 1 mL fecal extraction
buffer (0.1 mol/L Tris, 0.15 mol/L MaCl, 1.0 mol/L urea,
10 mmol/L CaCl2, 0.1 mol/L citric acid, 5 g/L bovine serum
albumin, 0.25 mmol/L thimerosal, pH 8; Hycult Biotech,
Wayne, PA). The supernatant was collected after the pellet
was broken up with vortexing and ceramic beads. The dilu-
tion with extraction buffer was calculated assuming a density
of 1 mg/mL and results were normalized to the stool weight.
Histologic Analysis
De-identified H&E-stained sections from DSS-treated
mice were scored by a pathologist according to published
methods.53 Briefly, the score is the sum of neutrophil infil-
tration (0–2), lymphocyte infiltration (0–2), erosion (0–3),
and crypt loss (0–2), with a maximum score of 9.
DSS Colitis
DSS salt (molecular weight, 36,000–50,000; MP Bio-
medicals, Irvine, CA) was added to drinking water for
1 week at 3% to induce severe colitis or 1.5% for mild/
moderate colitis. The solution was changed every 2–3 days.
Mice were observed daily and the DAI was calculated ac-
cording to published protocols.54 Briefly, the score given is
the average of a score for weight loss (0, none; 1, 2%–5%; 2,
5%–10%; 3, 10%–15%; 4, >15%), stool consistency
(0, normal; 2, loose stool; 4, diarrhea), and blood in stool
(0, negative; 2, guaiac positive, 4; gross bleeding).
Biotin Therapy
Biotin (Sigma-Aldrich) was dissolved in drinking water to
a concentration of 1 mmol/L. The solution was changed
every 2–3 days and mice received the treatment ad libitum.
FITC Dextran Permeability Assay
Intestinal permeability was determined in vivo using
methods previously described.55 Briefly, FITC-dextran (FD4;
Sigma-Aldrich) was dissolved in phosphate-buffered saline
to 100 mg/mL and administered to mice at 44 mg/100 gbody weight. Mice were fasted overnight and gavaged with
FITC-dextran on the last day of the experiment. After 4 hours,
mice were bled, plasma was separated, and measurements
were taken by fluorimeter at 488 nm (Synergy BioTek Plate
Reader, Winooski, VT). The concentration was calculated
based on a stander curve generated by serial dilutions of the
FITC-dextran stock in phosphate-buffered saline.
Quantitative Real-Time PCR Analysis
Total messenger RNA was isolated from the mouse distal
colon with Qiazol and the RNeasy Kit (Qiagen, Hilden Ger-
many) using 1.2-mm silica beads (Fisherbrand, Hampton,
NH). To remove DSS from purified messenger RNA we
performed further messenger RNA purification by lithium
chloride as described.56 Complementary DNA was synthe-
sized using the Verso complementary DNA synthesis kit
(Invitrogen, Carlsbad, CA). Expression levels of human
SMVT was determined using formalin-fixed paraffin-
embedded biopsy samples collected from the sigmoid colon
of patients at University of California Irvine with moderate/
severe UC. RNA was purified from the samples using the
Quick-RNA Formalin-Fixed Paraffin-Embedded Kit (Zymo
Research, Irvine, CA). Samples were quantified by real-time
quantitative PCR using gene-specific primers (Table 1) with
a CFX96 real-time iCycler (Bio-Rad, Hercules, CA). SYBR
green was used for mouse complementary DNA samples,
and the iTaq Universal One-Step Kit (Bio-Rad) was used for
human RNA samples.
Western Blot
For Western blot analysis, tissues/cells were homoge-
nized in RIPA buffer (Sigma) containing complete protease
inhibitor cocktail (Roche, Basel, Switzerland) using 1.2-mm
silica beads (Fisher, Hampton, NH) and the Fisherbrand
Bead Mill 24 Homogenizer. Total protein homogenates were
cleared by centrifugation at 12,000g for 20 minutes, and an
equal amount (65 mg) of the total proteins was loaded on a
4%–12% mini gel (Invitrogen). The proteins then were
transferred to a polyvinylidene difluoride membrane and
probed simultaneously with anti-mouse SMVT, NF-kB,
phospho NF-kB p65 (ser536) (raised in rabbit), and mono-
clonal b-actin antibody (raised in mouse). The blots then
566 Skupsky et al Cellular and Molecular Gastroenterology and Hepatology Vol. 9, No. 4were incubated with anti-rabbit/anti-mouse IR 800 dye and
anti-mouse IR 680 dye (LI-COR, Lincoln, NE) secondary
antibodies (1:25,000) for 1 hour at room temperature.
Relative expression was quantified by comparing the fluo-
rescence intensities in an Odyssey Infrared imaging system
(LI-COR) using Odyssey application software (version 3.0)
with respect to corresponding b-actin.
Statistical Analysis
The data are expressed as means ± SEM. Differences
were analyzed by a Student t test and was considered sig-
nificant when the P value was less than .05. Experiments
were performed at least 3 times to confirm consistent re-
sults and data from the most recent experiment are shown.References
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